Loading...
•
Mar 31, 2023
Biogen Q1 2023 Earnings Report
Biogen reported first quarter results and reaffirmed full year guidance.
Key Takeaways
Biogen's first quarter 2023 revenue reached $2,463 million, with a GAAP diluted EPS of $2.67 and a Non-GAAP diluted EPS of $3.40. The company is focused on potential launches in Alzheimer’s disease and ALS, while also prioritizing R&D and optimizing its operating model.
Continued progress on three potential launches in 2023.
LEQEMBI FDA Accelerated Approval received; traditional approval filing submitted.
Zuranolone New Drug Application accepted in the U.S. with Priority Review.
Advisory Committee agreed on potential clinical benefit of tofersen for SOD1-ALS.
Biogen
Biogen
Biogen Revenue by Segment
Biogen Revenue by Geographic Location
Revenue by Segment
Multiple Sclerosis Revenue
CapyFin.comBiosimilars Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
Biogen reaffirms its full year 2023 guidance, expecting a mid-single digit percentage decline in total revenue versus 2022 and Non-GAAP diluted EPS between $15.00 and $16.00.
Positive Outlook
- Guidance assumes foreign exchange rates as of March 31, 2023, will remain in effect for the remainder of the year, net of hedging activities.
- Reaffirms full year 2023 revenue guidance.
- Reaffirms full year 2023 Non-GAAP diluted EPS guidance.
- Focus on execution of three potential launches in 2023.
- Diligent in prioritizing R&D pipeline.
Challenges Ahead
- Guidance does not include any impact from potential acquisitions or large business development transactions or pending and future litigation, as all are hard to predict.
- Guidance does not include any impact of potential tax or healthcare reform.
- Potential acquisitions or large business development transactions could cause actual results to vary from this financial guidance.
- Pending and future litigation could cause actual results to vary from this financial guidance.
- Potential tax or healthcare reform could cause actual results to vary from this financial guidance.
Revenue & Expenses
Visualization of income flow from segment revenue to net income